SMARCA4 and lung adenocarcinoma: The majority of the reports evaluating the histopathology of SMARCA4 altered lung adenocarcinomas have concentrated in tumors with loss of immunohistochemical BRG1 expression [37], [38], [39], [40] and, presumably truncating SMARCA4 variants.